{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:07:34Z","timestamp":1789985254425,"version":"4.0.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:named-content content-type=\"genus-species\">Francisella tularensis<\/jats:named-content>, the Gram-negative bacterium that causes tularemia, is considered a potential bioterrorism threat due to its low infectivity dose and the high morbidity and mortality from respiratory disease. We previously characterized two mouse monoclonal antibodies (MAbs) specific for the<jats:italic>O<\/jats:italic>-polysaccharide (O antigen [OAg]) of<jats:named-content content-type=\"genus-species\">F. tularensis<\/jats:named-content>lipopolysaccharide (LPS): Ab63, which targets a terminal epitope at the nonreducing end of OAg, and Ab52, which targets a repeating internal OAg epitope. These two MAbs were protective in a mouse model of respiratory tularemia. To determine whether these epitope types are also targeted by humans, we tested the ability of each of 18 blood serum samples from 11 tularemia patients to inhibit the binding of Ab63 or Ab52 to<jats:named-content content-type=\"genus-species\">F. tularensis<\/jats:named-content>LPS in a competition enzyme-linked immunosorbent assay (ELISA). Although all serum samples had Ab63- and Ab52-inhibitory activities, the ratios of Ab63 to Ab52 inhibitory potencies varied 75-fold. However, the variation was only 2.3-fold for sequential serum samples from the same patient, indicating different distributions of terminal- versus internal-binding antibodies in different individuals. Western blot analysis using class-specific anti-human Ig secondary antibodies showed that both terminal- and internal-binding OAg antibodies were of the IgG, IgM, and IgA isotypes. These results support the use of a mouse model to discover protective B-cell epitopes for tularemia vaccines or prophylactic\/therapeutic antibodies, and they present a general strategy for interrogating the antibody responses of patients and vaccinees to microbial carbohydrate epitopes that have been characterized in experimental animals.<\/jats:p>","DOI":"10.1128\/cvi.00626-13","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T02:43:18Z","timestamp":1387420998000},"page":"227-233","source":"Crossref","is-referenced-by-count":9,"title":["Antibodies to Both Terminal and Internal B-Cell Epitopes of Francisella tularensis<i>O<\/i>-Polysaccharide Produced by Patients with Tularemia"],"prefix":"10.1128","volume":"21","author":[{"given":"Zhaohua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary M.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2013,12,18]]},"reference":[{"key":"key20180919073722_B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.micro.60.080805.142126","article-title":"Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare","volume":"60","author":"McLendon","year":"2006","journal-title":"Annu. Rev. Microbiol."},{"key":"key20180919073722_B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1409.009","article-title":"Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations","volume":"1105","author":"Sj\u00f6stedt","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073722_B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.idc.2009.10.012","article-title":"Tularemia pneumonia","volume":"24","author":"Thomas","year":"2010","journal-title":"Infect. Dis. Clin. North Am."},{"key":"key20180919073722_B4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1196\/annals.1409.017","article-title":"New approaches to diagnosis and therapy of tularemia","volume":"1105","author":"Tarnvik","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073722_B5","doi-asserted-by":"publisher","first-page":"D48","DOI":"10.1016\/j.vaccine.2009.07.090","article-title":"Francisella tularensis vaccines","volume":"27","author":"Oyston","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073722_B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/fmb.11.22","article-title":"Tularemia vaccines: recent developments and remaining hurdles","volume":"6","author":"Conlan","year":"2011","journal-title":"Future Microbiol."},{"key":"key20180919073722_B7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1196\/annals.1409.014","article-title":"Innate and adaptive immunity to Francisella","volume":"1105","author":"Elkins","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073722_B8","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/IAI.64.8.3288-3293.1996","article-title":"Minimal requirements for murine resistance to infection with Francisella tularensis LVS","volume":"64","author":"Elkins","year":"1996","journal-title":"Infect. Immun."},{"key":"key20180919073722_B9","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1128\/IAI.73.5.2644-2654.2005","article-title":"Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A","volume":"73","author":"Wu","year":"2005","journal-title":"Infect. Immun."},{"key":"key20180919073722_B10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/IAI.60.1.84-89.1992","article-title":"In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies","volume":"60","author":"Leiby","year":"1992","journal-title":"Infect. Immun."},{"key":"key20180919073722_B11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/IAI.67.4.1789-1797.1999","article-title":"Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice","volume":"67","author":"Stenmark","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073722_B12","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1128\/IAI.67.11.6002-6007.1999","article-title":"Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain","volume":"67","author":"Elkins","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073722_B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00000441-199408000-00003","article-title":"Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine","volume":"308","author":"Drabick","year":"1994","journal-title":"Am. J. Med. Sci."},{"key":"key20180919073722_B14","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1128\/IAI.59.9.2922-2928.1991","article-title":"Live vaccine strain of Francisella tularensis: infection and immunity in mice","volume":"59","author":"Fortier","year":"1991","journal-title":"Infect. Immun."},{"key":"key20180919073722_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-194002000-00001","article-title":"Tularemia: a summary of certain aspects of disease including methods for early diagnosis and the results of serum treatment in 600 patients","volume":"19","author":"Foshay","year":"1940","journal-title":"Medicine"},{"key":"key20180919073722_B16","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1016\/S0264-410X(01)00189-X","article-title":"Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis","volume":"19","author":"Fulop","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073722_B17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4049\/jimmunol.179.1.532","article-title":"Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis","volume":"179","author":"Kirimanjeswara","year":"2007","journal-title":"J. Immunol."},{"key":"key20180919073722_B18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-065X.2008.00689.x","article-title":"Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis","volume":"225","author":"Kirimanjeswara","year":"2008","journal-title":"Immunol. Rev."},{"key":"key20180919073722_B19","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1016\/j.vaccine.2008.09.077","article-title":"Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody","volume":"26","author":"Klimpel","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073722_B20","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1128\/IAI.62.8.3129-3137.1994","article-title":"Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells","volume":"62","author":"Rhinehart-Jones","year":"1994","journal-title":"Infect. Immun."},{"key":"key20180919073722_B21","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1128\/IAI.01789-06","article-title":"A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity","volume":"75","author":"Sebastian","year":"2007","journal-title":"Infect. Immun."},{"key":"key20180919073722_B22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0882-4010(03)00095-0","article-title":"Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica","volume":"35","author":"Stenmark","year":"2003","journal-title":"Microb. Pathog."},{"key":"key20180919073722_B23","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1016\/S0264-410X(02)00345-6","article-title":"Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen","volume":"20","author":"Conlan","year":"2002","journal-title":"Vaccine"},{"key":"key20180919073722_B24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1196\/annals.1409.006","article-title":"The structure and function of Francisella lipopolysaccharide","volume":"1105","author":"Gunn","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073722_B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1099\/jmm.0.05184-0","article-title":"Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis","volume":"52","author":"Prior","year":"2003","journal-title":"J. Med. Microbiol."},{"key":"key20180919073722_B26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1099\/jmm.0.45931-0","article-title":"Structural analysis of the O-antigen of Francisella tularensis subspecies tularensis strain OSU 10","volume":"54","author":"Thirumalapura","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"key20180919073722_B27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0008-6215(91)80036-M","article-title":"Structure of the O-antigen of Francisella tularensis strain 15","volume":"214","author":"Vinogradov","year":"1991","journal-title":"Carbohydr. Res."},{"key":"key20180919073722_B28","doi-asserted-by":"publisher","first-page":"10941","DOI":"10.1021\/bi201450v","article-title":"A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides","volume":"50","author":"Wang","year":"2011","journal-title":"Biochemistry"},{"key":"key20180919073722_B29","doi-asserted-by":"publisher","first-page":"e11060","DOI":"10.1371\/journal.pone.0011060","article-title":"Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis","volume":"5","author":"Apicella","year":"2010","journal-title":"PLoS One"},{"key":"key20180919073722_B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.imlet.2007.07.006","article-title":"Generation and characterization of hybridoma antibodies for immunotherapy of tularemia","volume":"112","author":"Lu","year":"2007","journal-title":"Immunol. Lett."},{"key":"key20180919073722_B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hyb.2010.0083","article-title":"Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide","volume":"30","author":"Roche","year":"2011","journal-title":"Hybridoma (Larchmt.)"},{"key":"key20180919073722_B32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/imm.12150","article-title":"The binding sites of monoclonal antibodies to the nonreducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide","volume":"140","author":"Lu","year":"2013","journal-title":"Immunology"},{"key":"key20180919073722_B33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2567.2012.03589.x","article-title":"Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia","volume":"136","author":"Lu","year":"2012","journal-title":"Immunology"},{"key":"key20180919073722_B34","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1021\/bi201711m","article-title":"Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide","volume":"51","author":"Rynkiewicz","year":"2012","journal-title":"Biochemistry"},{"key":"key20180919073722_B35","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1073\/pnas.060022997","article-title":"Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity","volume":"97","author":"Villeneuve","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073722_B36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bst0210437","article-title":"Recognition of a carbohydrate antigenic determinant of Salmonella by an antibody","volume":"21","author":"Cygler","year":"1993","journal-title":"Biochem. Soc. Trans."},{"key":"key20180919073722_B37","doi-asserted-by":"publisher","first-page":"6423","DOI":"10.1073\/pnas.91.14.6423","article-title":"Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution","volume":"91","author":"Zdanov","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073722_B38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.1440-1843.2001.00336.x","article-title":"Community-acquired pneumonia in patients requiring hospitalization","volume":"6","author":"Liam","year":"2001","journal-title":"Respirology"},{"key":"key20180919073722_B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/CVI.00516-12","article-title":"Detection of Francisella tularensis-specific antibodies in patients with tularemia by a novel competitive enzyme-linked immunosorbent assay","volume":"20","author":"Sharma","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073722_B40","doi-asserted-by":"publisher","first-page":"e68304","DOI":"10.1371\/journal.pone.0068304","article-title":"Antibodies to polymorphic invasion-inhibitory and non-nhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria","volume":"8","author":"Mugyenyi","year":"2013","journal-title":"PLoS One"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00626-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:25Z","timestamp":1627591825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00626-13"}},"subtitle":[],"editor":[{"given":"P. P.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,18]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,29]]},"published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/CVI.00626-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00626-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,18]]}}}